Form 4: Ultragenyx CAO Theodore Huizenga Receives Equity Grant

Ultragenyx Pharmaceutical Inc. SVP and Chief Accounting Officer Theodore Huizenga was granted 20,241 restricted stock units and 7,348 stock options.

Summary

• Theodore Huizenga, SVP and Chief Accounting Officer of Ultragenyx Pharmaceutical Inc., received an equity compensation package on April 22, 2026.
• The grant includes 20,241 Restricted Stock Units (RSUs) vesting over four years.
• The grant also includes 7,348 stock options with an exercise price of $24.61, expiring on April 22, 2036.
• Following these transactions, the reporting person holds 68,911 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation, which carries a neutral sentiment for investors.

Positives

• Equity-based compensation aligns the interests of the Chief Accounting Officer with long-term shareholder value.
• The multi-year vesting schedule for both RSUs and options serves as a retention mechanism for key executive talent.

Negatives

• The issuance of new equity awards results in minor dilution to existing shareholders.

Risks

• Future share price volatility may impact the ultimate value realized by the executive from these equity grants.
• Vesting is subject to continued employment, creating potential turnover risk if the executive departs before full vesting.

Future Outlook

The equity grants are subject to standard vesting schedules: RSUs vest 1/4th annually over four years, and options vest 1/4th on the first anniversary followed by monthly vesting over the subsequent three years.

Management Comments

• The filing does not contain narrative management commentary.

Industry Context

StockSavvy.ai notes that equity-based compensation is standard practice in the biotechnology sector to attract and retain specialized accounting and financial leadership, particularly for companies in the RARE disease space.

Comparison to Industry Standards

• The use of 4-year vesting schedules for executive equity is consistent with standard corporate governance practices in the U.S. biotech industry.
• The grant of both RSUs and stock options is a common dual-incentive structure used by mid-cap pharmaceutical firms.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of 1/4th of the RSU grant on April 22, 2027.
• Vesting of 1/4th of the stock options on April 22, 2027.

Key Dates

Keywords

Ultragenyx, RARE, Form 4, Executive Compensation, Insider Trading, Equity Grant, Biotech